Role of XPO1 Inhibitors in the Treatment of Relapsed/Refractory Multiple Myeloma

News
Video

Saad Usmani, MD, MBA, FACP, discusses the updates of XPO1 inhibitors in relapsed/refractory multiple myeloma patients.

Related Videos
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Related Content